Risk Stratification

GARFIELD-AF collects data on all components of the CHA2DS2-VASc and HAS-BLED risk stratification schemes to assess the risks of stroke and bleeding retrospectively.

Key Data:

  • GARFIELD-AF has confirmed that CHA2DS2-VASc and HAS-BLED are both predictive of the risk of major outcomes (stroke/systemic embolism, major bleeding and mortality), and may provide value in guiding physicians in clinical decision-making
    • Anticoagulation therapy, received by over 60% of patients in GARFIELD-AF cohorts 1 and 2, was associated with a substantially lower risk (35%) of all-cause death at 2-year follow-up
    • The most common causes of death are not known to be significantly influenced by anticoagulation, which suggests that a more comprehensive approach to the management of AF may be needed to reduce the risk of death

Key Publications:

Related Publications

Click to view publications related to Risk Stratification... [read more]

27 Jun 17

Global status

Read more
Total patients 57,262
Recruitment Recruitment closed
Follow-up Ongoing
Study end: 2018

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup






Please see our Privacy Policy and Cookie Policy

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

E: garfield@tri-london.ac.uk
T: 0203 198 9947